1719 related articles for article (PubMed ID: 10704204)
1. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
Rochet JC; Conway KA; Lansbury PT
Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144
[TBL] [Abstract][Full Text] [Related]
3. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
4. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
[TBL] [Abstract][Full Text] [Related]
5. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
Bickle L; Hopwood JJ; Karageorgos L
Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442
[TBL] [Abstract][Full Text] [Related]
6. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.
Cohlberg JA; Li J; Uversky VN; Fink AL
Biochemistry; 2002 Feb; 41(5):1502-11. PubMed ID: 11814343
[TBL] [Abstract][Full Text] [Related]
7. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?
Shtilerman MD; Ding TT; Lansbury PT
Biochemistry; 2002 Mar; 41(12):3855-60. PubMed ID: 11900526
[TBL] [Abstract][Full Text] [Related]
8. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
Li J; Uversky VN; Fink AL
Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils.
Bodles AM; Guthrie DJ; Harriott P; Campbell P; Irvine GB
Eur J Biochem; 2000 Apr; 267(8):2186-94. PubMed ID: 10759841
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
[TBL] [Abstract][Full Text] [Related]
11. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.
Bussell R; Eliezer D
Biochemistry; 2004 Apr; 43(16):4810-8. PubMed ID: 15096050
[TBL] [Abstract][Full Text] [Related]
12. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Volles MJ; Lansbury PT
Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
[TBL] [Abstract][Full Text] [Related]
13. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
El-Agnaf OM; Jakes R; Curran MD; Wallace A
FEBS Lett; 1998 Nov; 440(1-2):67-70. PubMed ID: 9862427
[TBL] [Abstract][Full Text] [Related]
14. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
[TBL] [Abstract][Full Text] [Related]
15. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
Volles MJ; Lee SJ; Rochet JC; Shtilerman MD; Ding TT; Kessler JC; Lansbury PT
Biochemistry; 2001 Jul; 40(26):7812-9. PubMed ID: 11425308
[TBL] [Abstract][Full Text] [Related]
16. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.
El-Agnaf OM; Irvine GB
J Struct Biol; 2000 Jun; 130(2-3):300-9. PubMed ID: 10940234
[TBL] [Abstract][Full Text] [Related]
17. PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly.
Ghee M; Melki R; Michot N; Mallet J
FEBS J; 2005 Aug; 272(16):4023-33. PubMed ID: 16098186
[TBL] [Abstract][Full Text] [Related]
18. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
[TBL] [Abstract][Full Text] [Related]
19. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores.
Bayer TA; Jäkälä P; Hartmann T; Havas L; McLean C; Culvenor JG; Li QX; Masters CL; Falkai P; Beyreuther K
Neurosci Lett; 1999 May; 266(3):213-6. PubMed ID: 10465711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
